Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo. Patients with resectable (surgically unremovable) non-small cell lung cancer ...

(Reuters) -Bristol Myers Squibb Co said on Tuesday its blockbuster cancer immunotherapy, Opdivo, in combination with chemotherapy improved survival in patients with a type of bladder cancer in a ...

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small ...

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...

On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...

FILE PHOTO: Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration (Reuters) - Bristol Myers Squibb said on Thursday the injectable form of its blockbuster cancer ...

Application based on CheckMate -816, the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in this setting If ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...

Ontario becomes the first province to list the combination under the new FAST pilot program, supporting timely access for eligible patients MONTREAL, Dec. 17, 2025 /CNW/ - Bristol Myers Squibb Canada ...